A helminth-induced mucosal Th2 response alters nonresponsiveness to oral administration of a soluble antigen.
A fascinating feature of the intestinal mucosal immune system is its ability to guard against invasion by pathogens while avoiding a response to the many potential Ags present in food. The phenomenon of systemic tolerance after oral administration of protein Ags is well documented, but the cellular and molecular basis for the observed nonresponsiveness is not fully understood. To gain insight into the role of the mucosal microenvironment in the induction of orally induced nonresponsiveness, we attempted to induce tolerance to OVA in mice primed for a Th2-biased mucosal immune response by infection with the nematode parasite Heligmosomoides polygyrus. We found that oral tolerance for Th1-type responses to OVA is maintained when OVA is fed during the peak of the mucosal immune response to H. polygyrus. Tolerance for Th2 cytokine responses or a Th2-dependent isotype of IgG is not induced in this Th2-biased mucosal environment. Treatment of infected mice with rIL-12 to reverse the Th2 polarity of the parasite-specific immune response restores tolerance of both Th1 and Th2 responses to OVA. We conclude that the polarized Th2 response induced by this enteric infection plays a central role in determining whether or not systemic tolerance is induced. Our results imply that attempts to use oral administration of Ag to suppress systemic immune responses will be influenced strongly by the presence of mucosal infection.
Shi
H N
HN
Mucosal Immunology Lab, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA.
Ingui
C J
CJ
Dodge
I
I
Nagler-Anderson
C
C
D000284:Administration, Oral; D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D007108:Immune Tolerance / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000494:pharmacology; D018664:Interleukin-12 / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000276:immunology* / Q000469:parasitology; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D009351:Nematospiroides dubius / Q000187:drug effects / Q000276:immunology*; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology; D012995:Solubility; D017206:Strongylida Infections / Q000276:immunology / Q000628:therapy; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism / Q000469:parasitology
D000909:Antibodies, Helminth; D000941:Antigens; D016207:Cytokines; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D018664:Interleukin-12; D010047:Ovalbumin